title: Novel pharmacotherapies of familial hyperlipidemia.
abstract: Familial hyperlipidemia is an inherited metabolic disorder characterized by elevated lipid and/or lipoprotein levels in the blood. Despite improvements in lipid-lowering therapy during the last decades, it still remains a substantial contributor to the incidence of cardiovascular disease since patients on current conventional therapies do not achieve their target LDL-cholesterol levels. With a view to lower LDL-cholesterol levels, a number of new therapeutic strategies have been developed over recent years. In this review, we provide an overview of these treatment options that are currently in clinical development and may offer alternative or adjunctive therapies for this high-risk population.
authors: 1st Department of Cardiology, Athens Medical School, Hippokration Hospital, Athens, Greece.
authors: Maria
authors: M
authors: Drakopoulou
authors: Konstantinos
authors: K
authors: Toutouzas
authors: Christodoulos
authors: C
authors: Stefanadis
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood; D015195:Drug Design; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents
keywords: ApolipoproteinB inhibitors; Cholesterol ester transfer protein inhibitors; Familial hypercholesterolemia; HDL-C; LDL-C; LDL-lowering therapy; MTP; Microsomal triglyceride transfer protein inhibitors; PCSK9; Protein convertase subtilisin/kexin type 9 inhibitors; high-density lipoprotein cholesterol; low-density lipoprotein cholesterol; microsomal triglyceride transfer protein; protein convertasesubtilisin/kexin type 9